Tag Archives: Motley Fool

Amgen’s osteoporosis med almost a home run in latest trial; fate now murky on heart safety






The News: Amgen Inc. (Thousand Oaks CA) and UCB SA (Brussels) no longer expect their experimental osteoporosis drug to win US approval this year after a higher rate of serious… Read more »

Pfizer’s mixed 1Q results spur M&A hopes; is Bristol-Myers a “done deal”?






The News: Pfizer Inc. said Tuesday (May 2, 2017) that first-quarter sales declined 2% year-over-year to $12.8 billion, missing analyst estimates of $13.1 billion, with the company highlighting one less… Read more »

Week’s opening stock salvo: Cleveland BioLabs, ImmunoGen lead winners; XBiotech, OncoMed crash






Among the top winners and losers in the healthcare sector last week, the following four were standouts and bear watching or acting upon, depending, as always, on one’s risk tolerance…. Read more »

Cardinal Health does face plant on skanky earnings guidance; even deal for some Medtronic assets raises concerns






The News: Cardinal Health Inc. (Dublin OH) struck a deal to buy part of Medtronic PLC’s (Dublin IRL) patient monitoring and recovery unit for $6.1 billion, bringing businesses under Cardinal’s roof… Read more »

Healthcare stocks have rough week as TherapeuticsMD, NantHealth fall flat; but Neurocrine, Tocagen shine






TherapeuticsMD Inc.(NYSE: TXMD) led a large contingent of stocks performing faceplants among the healthcare ranks. The clinical-stage biotech company focused on women’s health, plummeted $2.19, or 28%, to $7.70 in… Read more »

Week’s opening stock roundup: gainers include Novocure, Steadymed; but Corvus, NewLink rocked






Here to start your trading week are the major movers from last week and where they stand this morning: Novocure (Nasdaq: NVCR) led advancing issues, soaring $3.25, or 40% over the… Read more »

Marathon’s defense of pricey orphan drug getting spotlight in Congress; running a marathon is far easier, and a lot cheaper






Steve’s Take: Marathon Pharmaceuticals LLC (Northbrook IL) caught my attention last month at the inception of an outcry when the company first announced the $89,000 price tag for its newly… Read more »

Valeant CEO tries to paint happy face on 4Q results; markets not buying the turnaround–yet?






The News: Valeant Pharmaceuticals International Inc.’s (Laval Quebec) fourth-quarter loss widened to $515 million versus $385 million in the same period of 2015, as sales plummeted 13% year-over-year to $2.4… Read more »

Federal judge blocks $54-billion Anthem, Cigna merger; judiciary giving notice who’s boss in court






The News: A federal judge last week (February 6, 2017) blocked health insurer Anthem Inc. (Indianapolis IN) from acquiring rival Cigna Corp. (Bloomfield CT), the second court ruling in recent… Read more »

Gilead’s slog downward accelerates; CEO’s growth reassurances need action–now






The News: Gilead Sciences Inc. (Foster City CA) on Tuesday (February 7, 2017) said that it anticipates full-year revenue for 2017 to be in the range of $22.5 billion to… Read more »